The "Checkpoint Inhibitor Refractory Cancer Drugs Market -- Growth, Share, Opportunities & Competitive Analysis, 2025 -- 2032" report has been added to the Credence Research Inc. offering. The global ...
ACR-368, a CHK1/2 inhibitor in a registrational-intent Phase 2b study, showed potent preclinical synergy with Topoisomerase 1 (Topo 1) inhibitors, commonly used payloads in antibody-drug conjugates ...
Extended long-term survival observed after an additional year of follow-up in ongoing phase 2a clinical trial, with 50% of 46 ...
Checkpoint inhibitors are a groundbreaking class of cancer treatment, but they come with two frustrating challenges. In some cases, tumors show no initial response, rendering the therapy ineffective ...
Please provide your email address to receive an email when new articles are posted on . DESTIN, Fla. — Inflammatory arthritis as a result of immune checkpoint cancer therapy remains a pressing ...
Therapeutic progress in lung squamous cell carcinoma has lagged, with recent antiangiogenic–checkpoint inhibitor combinations ...
Please provide your email address to receive an email when new articles are posted on . Adding immune checkpoint inhibitors to neoadjuvant chemotherapy benefited certain patients with early-stage ...
MSI-H mCRC patients receiving ICIs had significantly improved OS compared to chemotherapy, with a 63% improvement in survival. MSS patients with high albumin levels or recent antibiotic use also ...
Immune checkpoint inhibitors, designed to block tumors from weakening the body’s immune activity, have been found to interfere with immune regulation in the heart. This side effect may lead to an ...
A nationwide cohort study in Taiwan found a higher risk of psoriasis in cancer patients treated with immune checkpoint inhibitors compared to other therapies. The study analyzed data from 3,188 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results